| Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised … SV Rajkumar, S Jacobus, NS Callander, R Fonseca, DH Vesole, ... The lancet oncology 11 (1), 29-37, 2010 | 1194 | 2010 |
| Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis H Uno, B Claggett, L Tian, E Inoue, P Gallo, T Miyata, D Schrag, ... Journal of clinical Oncology 32 (22), 2380, 2014 | 630 | 2014 |
| Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib N Wagle, BC Grabiner, EM Van Allen, E Hodis, S Jacobus, JG Supko, ... Cancer discovery 4 (5), 546-553, 2014 | 296 | 2014 |
| Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and … TK Choueiri, S Jacobus, J Bellmunt, A Qu, LJ Appleman, C Tretter, ... Journal of clinical oncology 32 (18), 1889, 2014 | 280 | 2014 |
| Triplet therapy, transplantation, and maintenance until progression in myeloma PG Richardson, SJ Jacobus, EA Weller, H Hassoun, S Lonial, NS Raje, ... New England Journal of Medicine 387 (2), 132-147, 2022 | 231 | 2022 |
| Randomized trial of lenalidomide versus observation in smoldering multiple myeloma S Lonial, S Jacobus, R Fonseca, M Weiss, S Kumar, RZ Orlowski, ... Journal of Clinical Oncology 38 (11), 1126, 2020 | 223 | 2020 |
| Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem … SK Kumar, SJ Jacobus, AD Cohen, M Weiss, N Callander, AK Singh, ... The Lancet Oncology 21 (10), 1317-1330, 2020 | 207 | 2020 |
| Clinical and biological significance of RAS mutations in multiple myeloma WJ Chng, N Gonzalez-Paz, T Price-Troska, S Jacobus, SV Rajkumar, ... Leukemia 22 (12), 2280-2284, 2008 | 207 | 2008 |
| Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations WJ Chng, R Santana-Davila, SA Van Wier, GJ Ahmann, SM Jalal, ... Leukemia 20 (5), 807-813, 2006 | 179 | 2006 |
| Clinical significance of TP53 mutation in myeloma WJ Chng, T Price-Troska, N Gonzalez-Paz, S Van Wier, S Jacobus, ... Leukemia 21 (3), 582-584, 2007 | 177 | 2007 |
| Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer TK Choueiri, RW Ross, S Jacobus, U Vaishampayan, EY Yu, DI Quinn, ... Journal of Clinical Oncology 30 (5), 507-512, 2012 | 175 | 2012 |
| A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone‐refractory prostate cancer who are refractory to docetaxel RW Ross, TM Beer, S Jacobus, GJ Bubley, ME Taplin, CW Ryan, J Huang, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2008 | 145 | 2008 |
| A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial … SV Rajkumar, S Jacobus, N Callander, R Fonseca, D Vesole, M Williams, ... Blood 110 (11), 74, 2007 | 136 | 2007 |
| Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the … SV Rajkumar, S Jacobus, N Callander, R Fonseca, D Vesole, ... Journal of Clinical Oncology 26 (15_suppl), 8504-8504, 2008 | 115* | 2008 |
| Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by … SV Rajkumar, S Jacobus, N Callander, R Fonseca, D Vesole, M Williams, ... J Clin Oncol 25 (18 Suppl), 8025a, 2007 | 103 | 2007 |
| Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the … SV Rajkumar, S Jacobus, N Callander, R Fonseca, D Vesole, ... Journal of Clinical Oncology 26 (15_suppl), 8504-8504, 2008 | 99 | 2008 |
| Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma AK Stewart, S Jacobus, R Fonseca, M Weiss, NS Callander, ... Blood, The Journal of the American Society of Hematology 126 (11), 1294-1301, 2015 | 93 | 2015 |
| Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials S Ailawadhi, S Jacobus, R Sexton, AK Stewart, A Dispenzieri, ... Blood cancer journal 8 (7), 67, 2018 | 80 | 2018 |
| Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study DH Vesole, MM Oken, C Heckler, PR Greipp, MS Katz, S Jacobus, ... Leukemia 26 (12), 2517-2520, 2012 | 80 | 2012 |
| Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach A Baker, E Braggio, S Jacobus, S Jung, D Larson, T Therneau, ... Blood, The Journal of the American Society of Hematology 121 (16), 3147-3152, 2013 | 69 | 2013 |
